SAL061

SAL061 is an investigational long-acting small interfering RNA (siRNA) therapeutic developed by Shenzhen Salubris Pharmaceuticals for the treatment of dyslipidemia, specifically hypercholesterolemia. It is designed to target and silence the mRNA encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) in the liver. By inhibiting the synthesis of the PCSK9 protein, SAL061 prevents the degradation of low-density lipoprotein receptors (LDL-R) on the surface of hepatocytes. This leads to an increased density of LDL-R, which enhances the clearance of LDL cholesterol from the bloodstream. As an siRNA-based therapy, SAL061 is intended to provide a sustained lipid-lowering effect with infrequent dosing, potentially offering a therapeutic advantage over monoclonal antibodies in terms of patient compliance.